NASDAQ: TENXTenax Therapeutics Inc Stock
$10.55-0.18 (-1.68%)
Updated Jun 10, 2026
TENX Price
$10.55
Fair Value Price
$2.49
Market Cap
$279.84M
52 Week Low
$5.34
52 Week High
$18.38
P/E
-7.54x
P/B
2.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.91M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$38M
Beta
0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TENX Overview
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TENX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TENX
Ranked#275 of 462
Ranked#275 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.63 | A | |
| $52.58 | A | |
| $15.66 | A |
Be the first to know about important TENX news, forecast changes, insider trades & much more!
TENX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TENX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TENX ($10.55) is overvalued by 324.07% relative to our estimate of its Fair Value price of $2.49 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TENX ($10.55) is not significantly undervalued (324.07%) relative to our estimate of its Fair Value price of $2.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TENX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TENX due diligence checks available for Premium users.
Valuation
TENX fair value
Fair Value of TENX stock based on Discounted Cash Flow (DCF)
Price
$10.55
Fair Value
$2.49
Overvalued by
324.07%
TENX ($10.55) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TENX ($10.55) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TENX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TENX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.54x
Industry
18.33x
Market
14.77x
TENX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.44x
Industry
4.71x
TENX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TENX's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.7M
Profit Margin
0%
TENX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$123.2M
Liabilities
$8.5M
Debt to equity
0.07
TENX's short-term assets ($123.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TENX's short-term assets ($123.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TENX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TENX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.3M
Investing
$0.0
Financing
$30.5M
TENX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TENX vs Biotech Stocks
Tenax Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.